Particulars (Rupees in Crores.) | Sept-2024 | Mar-2024 | Sept-2023 | Mar-2023 | Sept-2022 |
---|---|---|---|---|---|
Gross Sales | 1,465.7 | 1,239.59 | 1,258.51 | 1,138.09 | 1,059.59 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 1,465.7 | 1,239.59 | 1,258.51 | 1,138.09 | 1,059.59 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 9.6 | 7.11 | 5.99 | 11.33 | 29.37 |
Total Income | 1,475.3 | 1,246.7 | 1,264.51 | 1,149.43 | 1,088.95 |
Total Expenditure | 1,068.2 | 933.9 | 924.2 | 823.68 | 769.99 |
PBIDT | 407.1 | 312.79 | 340.31 | 325.75 | 318.96 |
Interest | 37.8 | 28.76 | 18.24 | 16.94 | 13.61 |
PBDT | 369.3 | 284.03 | 322.07 | 308.81 | 305.36 |
Depreciation | 80 | 81.63 | 64.87 | 68.72 | 60.54 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 78.8 | 47.15 | 69.05 | 57.92 | 58.69 |
Deferred Tax | -5.4 | 7.22 | 0.18 | 1.66 | 0.82 |
Reported Profit After Tax | 215.9 | 148.04 | 187.97 | 180.5 | 185.31 |
Minority Interest After NP | 21.9 | 10.77 | 15.13 | 11.25 | 18.24 |
Net Profit after Minority Interest | 194 | 137.27 | 172.83 | 169.25 | 167.07 |
Extra-ordinary Items | 0 | 0 | 0 | 0 | 11.22 |
Adjusted Profit After Extra-ordinary item | 194 | 137.27 | 172.83 | 169.25 | 155.85 |
EPS (Unit Curr.) | 4.85 | 17.16 | 21.6 | 21.15 | 20.88 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 80 | 80 | 80.03 | 80.03 | 80.03 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 27.77 | 25.23 | 27.04 | 28.62 | 30.1 |
PBDTM(%) | - | - | - | - | - |
PATM(%) | 14.73 | 11.94 | 14.93 | 15.85 | 17.48 |
Here are some of the stocks that may see significant price movement today: GIC Re, GSK Pharma, Godfrey Philips, etc.
It has entered into a share purchase agreement to acquire a 100% equity stake in Chalasani Hospitals Pvt Ltd.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.